(:KITE)

Aug 31, 2017 07:23 pm ET
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Kite Pharma, Inc. - KITE
NEW YORK, Aug. 31, 2017 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a boutique securities firm headquartered at the Empire State Building in New York City, is investigating Kite Pharma, Inc. ("Kite Pharma" or the "Company") (NASDAQ: KITE) relating to the sale of the Company to affiliates of Gilead Sciences, Inc. (NASDAQ: GILD). As a result of the merger, Kite Pharma shareholders are only anticipated to receive $180.00 in cash in exchange for each share of Kite Pharma.
Aug 29, 2017 07:46 pm ET
Harwood Feffer LLP Announces Investigation of Kite Pharma, Inc.
NEW YORK, Aug. 29, 2017 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Kite Pharma, Inc. ("Kite" or the "Company") (NASDAQ: KITE) concerning the proposed acquisition of the Company by Gilead Sciences, Inc. ("Gilead").
Aug 28, 2017 10:31 am ET
Options Trader Alert: Covered-call reports released for Caterpillar Inc., Juno Therapeutics Inc, Kite Pharma, Southwest Airlines Co. and Ulta Salon Cosmetics & Fragrance Inc.
CHICAGO, Aug. 28, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CAT, JUNO, KITE, LUV, and ULTA.
May 09, 2017 10:31 am ET
Investors: Covered Call reports for Horizon Pharma, JD.com, JP Morgan Chase, Kite Pharma and Micron include trade ideas that offer returns of 20% or more!
CHICAGO, May 9, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HZNP, JD, JPM, KITE, and MU.
May 08, 2017 02:26 pm ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Kite Pharma, Inc. (KITE)
NEW YORK, May 8, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Kite Pharma, Inc. ("Kite" or the "Company") (NASDAQ: KITE). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/kite.
May 08, 2017 01:14 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kite Pharma, Inc. - KITE
NEW YORK, May 8, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kite Pharma, Inc. ("Kite" or the "Company") (NASDAQ: KITE).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
Dec 06, 2016 09:31 am ET
Nov 07, 2016 09:31 am ET
InvestorsObserver releases covered-call reports for ACADIA Pharmaceuticals, Valero Energy, Kite Pharma, Inovio Pharmaceuticals and Fitbit
CHICAGO, Nov. 7, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACAD, FIT, INO, KITE, and VLO.
Oct 18, 2016 10:31 am ET
Tesla Motors, Intel, Domino's Pizza, Teck Resources limited, and Kite Pharma and more offer option-trading opportunities that offer returns of more than 20%
CHICAGO, Oct. 18, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DPZ, INTC, KITE, TCK, and TSLA.
Sep 28, 2016 10:31 am ET
Prudential, Verizon Communications, Kite Pharma, TASER International, and Carnival Corporation and more offer option-trading opportunities that offer returns of more than 20%
CHICAGO, Sept. 28, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CCL, KITE, PRU, TASR, and VZ.
Sep 16, 2016 10:31 am ET
Covered Call reports for Disney, Kite Pharma, Ford, CONSOL Energy and Caterpillar Inc. include trade ideas that offer returns of 20% or more!
CHICAGO, Sept. 16, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CAT, CNX, DIS, F, and KITE.
May 02, 2016 04:05 pm ET
Kite Pharma Announces FDA Orphan Drug Designations for KTE-C19 in Five Additional Indications
All Hematological Malignancies Targeted by KTE-C19 Development Now Covered by Orphan Drug Designations in U.S. and EU...
Apr 28, 2016 07:00 am ET
Kite Pharma Announces Presentations at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
SANTA MONICA, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE) ("Kite") a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced four presentations to be delivered at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. The presentations will address KTE-C19, Kite's lead chimeric antigen receptor (CAR) product candidate, and, separately, a fully-human anti-CD19 CAR product candidate for the treatment of B-cell lymphomas and leukem...
Mar 02, 2016 09:31 am ET
Covered Call Alerts For Chesapeake Energy, Kite Pharma, Opko Health, Las Vegas Sands and 3D Systems Released By InvestorsObserver
CHICAGO, March 2, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CHK, KITE, OPK, LVS and DDD.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.